News
TXA 127 to enter phase II trials for COVID-19.- Constant Therapeutics
Constant Therapeutics announced that its peptide drug TXA 127, a pharmaceutical formulation of the natural human peptide angiotensin-(1-7), will be tested in a Phase II clinical trial at Columbia University Irving Medical Center in New York, New York. The double-blind, placebo-controlled trial will recruit 100 patients with COVID-19 who require oxygen but are not in the ICU. The endpoints include incidence of renal failure and incidence of respiratory failure. Further details of the study are posted on clinicaltrials.gov (NCT04401423). Comment:"We were interested in testing TXA127 because it is our hypothesis that the downregulation of ACE2 by SARS-CoV-2 may lead to an angiotensin-(1-7) deficiency and tilt the renin angiotensin signaling axis into a pro-inflammatory state. Supplementation with exogenous angiotensin-(1-7) with TXA127 has the potential to reverse this disruption," said Dr. Jeanine D'Armiento, MD, PhD, Professor of Medicine in Anesthesiology and Physiology and Cellular Biophysics at Columbia University Vagelos College of Physicians and Surgeons and Director of the Center for Molecular Pulmonary Disease at Columbia University Irving Medical Center. TXA127 is a Mas receptor agonist and has been shown in various animal models of lung injury to reduce inflammation, stabilize endothelial and epithelial barriers and reduce fibrosis.
Condition: Coronavirus/COVID-19 Infection
Type: drug